Vor Biopharma (VOR) Set to Announce Quarterly Earnings on Monday

Vor Biopharma (NYSE:VOR) is scheduled to announce its earnings results on Monday, April 29th.

Vor Biopharma (NYSE:VOR) last released its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.10. On average, analysts expect Vor Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vor Biopharma Stock Performance

VOR opened at $1.69 on Friday. The company’s 50 day simple moving average is $2.01 and its 200 day simple moving average is $2.11. Vor Biopharma has a 1 year low of $1.62 and a 1 year high of $5.70. The stock has a market capitalization of $115.29 million, a PE ratio of -0.96 and a beta of -0.36.

Analysts Set New Price Targets

A number of brokerages have weighed in on VOR. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target (down from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Friday, March 22nd. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a research note on Tuesday, April 23rd. Finally, Stifel Nicolaus dropped their price objective on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Vor Biopharma has an average rating of “Buy” and a consensus price target of $13.50.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.